Thermo Fisher (NYSE:TMO) agrees to acquire Brammer Bio for ~$1.7B in cash in a bid to expand its presence in the gene therapy field.
Brammer Bio, owned by P-E firm Ampersand Capital Partners, provides provides clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy, along with process and analytical development.
TMO says Brammer is on track to deliver $250M in revenue in 2019 and expects to continue to exceed the projected market growth rate of 25% over the mid-term.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.